In a phase 2 trial, monitoring tumor resistance mutations in blood using liquid biopsies allowed to rationally guide subsequent therapy with anti-EGFR antibodies in patients with ColorectalCancer. EGFR biomarkers Cancer Albert0Bardelli BardelliLab
, the protocol was specifically customized for cfDNA processing. Overall, based on the quality and the low quantity of starting material , library preparation was performed with specific adjustments, whereas the target enrichment was customized with the design of a small target panel.
Library preparation started directly with end-repair reaction by using NEBNext End Repair Module following the manufacturer’s protocol, therefore avoiding any fragmentation step. To minimize the loss of so short fragments )of low-input cfDNA, a clean-up step with an optimized ratio volume of AMPure XP beads was performed, without size selection.
The target of interest was defined starting from the identification of genes relevant for tumorigenesis, evolution and emergence of drug resistance in CRC. In detail, the genomic size of high-sensitivity capture LB panel is 59 kilobases for a total of 300 captured regions.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Choosing Wisely for oncology in Brazil: 10 recommendations to deliver evidence-based cancer care - Nature MedicineChoosing Wisely for oncology in Brazil: 10 recommendations to deliver evidence-based cancer care. Correspondence from Fabio Ynoe de Moraes and colleagues LACOG_group
Read more »
The uncertain science of preimplantation genetic testing in Japan - Nature MedicineThe uncertain science of preimplantation genetic testing in Japan. Correspondence from Mayumi Sugiura-Ogasawara & Takeshi Sato, Nagoya City University, Japan
Read more »
Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial - Nature MedicineThe SIGNAL Phase 2 study of pepinemab immunotherapy in early Huntington’s disease (HD) did not meet its coprimary clinical efficacy endpoints, but had a favorable safety profile and showed a significant treatment-related reduction in caudate brain atrophy and reversal of the characteristic decline in brain metabolic activity that is typical of HD progression.
Read more »
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial - Nature MedicineIn a phase 2 randomized clinical trial, an inhibitor of cholesteryl ester transfer protein (CETP), obicetrapib, lowered low-density lipoprotein cholesterol when administered in conjunction with high-intensity statins, paving the way for studies investigating the effects of obicetrapib on cardiovascular events.
Read more »
Doc Loses License Over 'Poor' Cancer Care, but Fights BackCanadian physician Akbar Khan, MD, has been stripped of his license to practice medicine for providing questionable care to cancer patients, but he is fighting back by filing criminal charges.
Read more »
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia - Nature MedicineSingle-cell genomic & transcriptomic analyses of longitudinal samples of patients with RichterSyndrome reveal the presence and dynamics of clones driving transformation from chronic lymphocytic leukemia years before clinical manifestation. FerranNadeu
Read more »